Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | CTSL | P07711 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8769007 | 1.00 | ABCG2 (0.80) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31611889 | 1.00 | ABCG2 (0.80) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30383668 | 0.90 | ABCG2 (0.80) | ABCG2FLT3MEN1LMNAHPGD | |
| SCHEMBL4969738 | 0.90 | ABCG2 (0.80) | ABCG2FLT3MEN1LMNAHPGD | |
| SCHEMBL13696689 | 0.90 | ABCG2 (0.80) | ABCG2FLT3MEN1LMNAHPGD | |
| SCHEMBL633909 | 0.88 | PDE4A (1.00) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL633910 | 0.88 | PDE4A (1.00) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL633045 | 0.88 | ABCG2 (0.97) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL633046 | 0.88 | ABCG2 (0.97) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL634098 | 0.87 | PDE4A (0.82) | ABCG2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0629602-B1 | 3,4-Dihydroxychalcone derivatives | NIPPON HYPOX LAB INC (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0629602-A1 | 3,4-Dihydroxychalcone derivatives | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-5276058-A | Antiinflammatory agents | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1994-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ABCG2 394/4885PDE4A 1820/4885PDE4B 1456/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ABCG2 394/4885PDE4A 1820/4885PDE4B 1456/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ABCG2 3751/4885PDE4A 182/4885PDE4B 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.